S Marnitz1, L Schermeyer2, S Dommerich3, C Köhler4, H Olze3, V Budach2, P Martus5. 1. Medical Faculty, Department of Radiation Oncology, CyberKnife Center, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. simone.marnitz-schulze@uk-koeln.de. 2. Department of Radiation Oncology, Charité University Clinic, Berlin, Germany. 3. Department of Otolaryngology, Head and Neck Surgery, Charité University Clinic, Berlin, Germany. 4. Department of Gynecologic Oncology, Asklepios Clinic Hamburg, Hamburg, Germany. 5. Institute of Clinical Epidemiology and Applied Biosta5s5cs, Eberhard-Karls-University Tübingen, Tübingen, Germany.
Abstract
OBJECTIVE: This study aimed to evaluate subjective and objective hearing loss in cervical cancer patients after chemoradiation with cisplatin (mono). PATIENTS AND METHODS: A total of 51 cervical cancer patients with indication for chemoradiation were included. Pure tone and impedance audiometry were performed before and after chemoradiation. Hearing loss was scaled according to ASHA criteria. Subjective hearing was assessed with the Oldenburger Sentence Test. To consider age-dependent changes, hearing loss was corrected for age and the time interval between measurements. RESULTS: Median age at diagnosis was 46 years, 46% were active/former smokers (n = 24), 28 (54%) patients were never-smokers. Median total weekly cisplatin dose was 70 ± 14.2 mg. Cumulative doses of cisplatin during chemoradiation ranged between 115.2 and 400 mg cisplatin (mean 336.1 mg, median 342 ± 52.7 mg). The median interval between last chemotherapy and second audiometry was 320 ± 538 days (35-2262 days). Changes in hearing threshold ≥20 dB were experienced by 32/52 patients (62%) following chemoradiation, 55% of them for frequencies ≥6000 Hz. No statistically significant hearing loss remained after chemoradiation upon correction for age and time interval. Patients >40 years had a higher risk of hearing loss than younger patients. Objective data on hearing function did not correlate with subjective hearing loss and did not impair daily activity in any patient. CONCLUSION: Chemoradiation with cumulative cisplatin doses up to 400 mg did not lead to significant impairment of objective or subjective hearing. For cervical cancer patients undergoing chemoradiation, standard audiometry is not indicated.
OBJECTIVE: This study aimed to evaluate subjective and objective hearing loss in cervical cancerpatients after chemoradiation with cisplatin (mono). PATIENTS AND METHODS: A total of 51 cervical cancerpatients with indication for chemoradiation were included. Pure tone and impedance audiometry were performed before and after chemoradiation. Hearing loss was scaled according to ASHA criteria. Subjective hearing was assessed with the Oldenburger Sentence Test. To consider age-dependent changes, hearing loss was corrected for age and the time interval between measurements. RESULTS: Median age at diagnosis was 46 years, 46% were active/former smokers (n = 24), 28 (54%) patients were never-smokers. Median total weekly cisplatin dose was 70 ± 14.2 mg. Cumulative doses of cisplatin during chemoradiation ranged between 115.2 and 400 mg cisplatin (mean 336.1 mg, median 342 ± 52.7 mg). The median interval between last chemotherapy and second audiometry was 320 ± 538 days (35-2262 days). Changes in hearing threshold ≥20 dB were experienced by 32/52 patients (62%) following chemoradiation, 55% of them for frequencies ≥6000 Hz. No statistically significant hearing loss remained after chemoradiation upon correction for age and time interval. Patients >40 years had a higher risk of hearing loss than younger patients. Objective data on hearing function did not correlate with subjective hearing loss and did not impair daily activity in any patient. CONCLUSION: Chemoradiation with cumulative cisplatin doses up to 400 mg did not lead to significant impairment of objective or subjective hearing. For cervical cancerpatients undergoing chemoradiation, standard audiometry is not indicated.
Authors: Robert D Frisina; Heather E Wheeler; Sophie D Fossa; Sarah L Kerns; Chunkit Fung; Howard D Sesso; Patrick O Monahan; Darren R Feldman; Robert Hamilton; David J Vaughn; Clair J Beard; Amy Budnick; Eileen M Johnson; Shirin Ardeshir-Rouhani-Fard; Lawrence H Einhorn; Steven E Lipshultz; M Eileen Dolan; Lois B Travis Journal: J Clin Oncol Date: 2016-06-27 Impact factor: 44.544
Authors: W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: Line V Hjelle; Per O M Gundersen; Jan Oldenburg; Marianne Brydøy; Torgrim Tandstad; Tom Wilsgaard; Sophie D Fosså; Roy M Bremnes; Hege S Haugnes Journal: Anticancer Res Date: 2015-03 Impact factor: 2.480
Authors: C Bokemeyer; C C Berger; J T Hartmann; C Kollmannsberger; H J Schmoll; M A Kuczyk; L Kanz Journal: Br J Cancer Date: 1998-04 Impact factor: 7.640